About Novomics
Novomics is a company based in Seoul (South Korea) founded in 2010. Novomics has raised $3.41 million across 2 funding rounds from investors including Yuanda Financial Holdings, Partners Group and ClinicalTrials.gov. Novomics operates in a competitive market with competitors including Guardant Health, Foundation Medicine, ArcherDX, Natera and Arbor Biotechnologies, among others.
- Headquarter Seoul, South Korea
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Novomics Co., Ltd
-
Annual Revenue
$4.63 K (USD)0as on Dec 31, 2019
-
Net Profit
-
EBITDA
-
Total Equity Funding
$3.41 M (USD)
in 2 rounds
-
Latest Funding Round
$3.41 M (USD), Series A
Dec 12, 2016
-
Investors
Yuanda Financial Holdings
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Novomics
Novomics has successfully raised a total of $3.41M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $3.41 million completed in December 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $3.4M
- First Round First Round
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2016 | Amount | Series A - Novomics | Valuation |
investors |
|
| Jun, 2015 | Amount | Series A - Novomics | Valuation |
investors |
|
Investors in Novomics
Novomics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Yuanda Financial Holdings, Partners Group and ClinicalTrials.gov.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A private investment holding company focused on middle market technology.
|
Founded Year | Domain | Location | |
|
Private equity funds are managed across multiple sectors globally.
|
Founded Year | Domain | Location | |
|
South-Korea based VC firm
|
Founded Year | Domain | Location |
Investments & Acquisitions by Novomics
Financial Statements - Novomics
Novomics Comparisons
Competitors of Novomics
Novomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Foundation Medicine, ArcherDX, Natera and Arbor Biotechnologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Digital sequencing technology for cancer detection is developed.
|
|
| domain | founded_year | HQ Location |
Genomics-based diagnostic tests for cancer are provided.
|
|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| domain | founded_year | HQ Location |
Genomic technologies and drug discovery platforms are provided.
|
|
| domain | founded_year | HQ Location |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
Frequently Asked Questions about Novomics
Novomics was founded in 2010 and raised its 1st funding round 5 years after it was founded.
Novomics is headquartered in Seoul, South Korea.
Huh Yongmin is the current CEO of Novomics.
Novomics is a funded company, having raised a total of $3.41M across 2 funding rounds to date.
Annual revenue of Novomics is $4.63K as on Dec 31, 2019.
Novomics was founded in 2010 in Seoul, South Korea, within the biotechnology sector. Molecular diagnostic systems for cancer are developed, focusing on assays that predict post-surgery prognosis in advanced gastric cancer. The flagship nProfiler-1 assay measures nine gene expressions via RT-qPCR, with analysis performed by the nDx-1 algorithm software. Companion diagnostics for lung and colorectal cancers are also under development using the same platform.
Novomics's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
Novomics has 5 investors. Key investors include Yuanda Financial Holdings, Partners Group, ClinicalTrials.gov, Mega Investment, and SV Investment Partners.